Michèle Cavo

1991–2025 年に発表

別表記
Michele Cavo
321
論文数
61,112
被引用数
120
h 指数
307
i10 指数

被引用数

Michèle Cavo の年別被引用数1948 年: 被引用 3 件1979 年: 被引用 3 件1984 年: 被引用 1 件1988 年: 被引用 3 件1990 年: 被引用 3 件1992 年: 被引用 2 件1993 年: 被引用 3 件1994 年: 被引用 6 件1995 年: 被引用 5 件1996 年: 被引用 10 件1997 年: 被引用 10 件1998 年: 被引用 14 件1999 年: 被引用 10 件2000 年: 被引用 21 件2001 年: 被引用 16 件2002 年: 被引用 27 件2003 年: 被引用 60 件2004 年: 被引用 46 件2005 年: 被引用 49 件2006 年: 被引用 44 件2007 年: 被引用 58 件2008 年: 被引用 62 件2009 年: 被引用 112 件2010 年: 被引用 127 件2011 年: 被引用 216 件2012 年: 被引用 158 件2013 年: 被引用 232 件2014 年: 被引用 309 件2015 年: 被引用 335 件2016 年: 被引用 375 件2017 年: 被引用 426 件2018 年: 被引用 335 件2019 年: 被引用 1,698 件2020 年: 被引用 2,083 件2021 年: 被引用 2,445 件2022 年: 被引用 2,083 件2023 年: 被引用 1,605 件2024 年: 被引用 2,915 件2025 年: 被引用 1,342 件2026 年: 被引用 43 件1949〜1978 年は被引用が無いため表示していません1980〜1983 年は被引用が無いため表示していません1985〜1987 年は被引用が無いため表示していません1989 年は被引用が無いため表示していません1991 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,765 件、この内訳の 23.2%イタリア: 引用元論文 1,285 件、この内訳の 7.9%ドイツ: 引用元論文 1,031 件、この内訳の 6.4%中国: 引用元論文 1,011 件、この内訳の 6.2%イギリス: 引用元論文 950 件、この内訳の 5.9%フランス: 引用元論文 901 件、この内訳の 5.6%スペイン: 引用元論文 819 件、この内訳の 5%オランダ: 引用元論文 542 件、この内訳の 3.3%カナダ: 引用元論文 507 件、この内訳の 3.1%オーストラリア: 引用元論文 428 件、この内訳の 2.6%ギリシャ: 引用元論文 408 件、この内訳の 2.5%ベルギー: 引用元論文 352 件、この内訳の 2.2%
0%23.2%その他 26.1%

分野

  • Medicine80.7%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology2.6%
  • Computer Science0.5%
  • Engineering0.4%
  • Nursing0.4%
  • その他1.6%

トピック

  • Multiple Myeloma Research and Treatments17%
  • Protein Degradation and Inhibitors6.7%
  • CAR-T cell therapy research5.8%
  • Peptidase Inhibition and Analysis3.9%
  • Amyloidosis: Diagnosis, Treatment, Outcomes2.8%
  • Cancer Treatment and Pharmacology2.6%
  • その他61.2%

共著者

全論文

検索で開く
  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 2,424

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau - The Lancet Oncology 2016 被引用: 2,995

  3. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert A. Kyle, Kenneth C. Anderson, Brian G.M. Durie, Jesús F. San Miguel - The Lancet Oncology 2014 被引用: 4,869

  4. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carolyn C. Jackson, Kaitlyn Connors, Katherine Li, Enrique Zudaire, Diana Chen, Jane Gilbert, Tzu‐Min Yeh, Sarah Nagle, Erika Florendo, Lida Pacaud, Nitin Patel, Simon J. Harrison, Hermann Einsele - New England Journal of Medicine 2023 被引用: 733

  5. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 705

  6. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Moreau - Journal of Clinical Oncology 2015 被引用: 2,178

  7. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau - New England Journal of Medicine 2023 被引用: 515

  8. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    著者: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 820

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld - Journal of Clinical Oncology 2022 被引用: 407

  10. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 178

  11. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 被引用: 240

  12. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 被引用: 380

  13. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn ほか 30 名 - The Lancet 2019 被引用: 636

  14. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 984

  15. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 被引用: 327

  16. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Baldeep Wirk, Matthew T. Drake, Michèle Cavo, Juan José Lahuerta, Suzanne Lentzsch - The Lancet Oncology 2019 被引用: 496

  17. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 404

  18. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Simon McNamara, Xiangdong Zhou, Maureen Nichols, Eric Lewis, Rachel Rogers, Hena Baig, Lydia Eccersley, Sumita Roy–Ghanta, Joanna Opalińska, María-Victoria Mateos - New England Journal of Medicine 2024 被引用: 166

  19. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 151

  20. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi - The Lancet 2020 被引用: 324

  21. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 1,054

  22. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 被引用: 244

  23. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2019 被引用: 438

  24. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Achilleas Anagnostopoulos, Larry D. Anderson, Pekka Anttila, Carla Araujo, Carlos Arce‐Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph V. Boccia, Lillian Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Gabrail, Barbara Gamberi, Mitchell Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid T. Hanna, Patrick Hayden, Maria Manuela Henriques Bernardo, Róbert Hermann, Viran Holden, Kirsti Honkalehto, Marianne Huben, John Huffman, Hannah Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael Jaiyesimi, Matthew Jenner, Cristina João, Peter Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham S. Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose ほか 65 名 - The Lancet Oncology 2019 被引用: 385